Algert Global LLC Has $825,000 Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Algert Global LLC lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 64.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,951 shares of the specialty pharmaceutical company’s stock after selling 23,629 shares during the period. Algert Global LLC owned approximately 0.06% of ANI Pharmaceuticals worth $825,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Innealta Capital LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $65,000. Ridgewood Investments LLC acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth about $85,000. SG Americas Securities LLC acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth about $106,000. ADAR1 Capital Management LLC acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter worth about $132,000. Finally, Clear Street Markets LLC acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter worth about $140,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ANIP. Truist Financial reissued a “hold” rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Raymond James boosted their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $78.80.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $57.83 on Friday. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of 36.14 and a beta of 0.71. The company has a 50-day moving average of $60.16 and a 200-day moving average of $63.13. ANI Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $70.81. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter last year, the company earned $1.06 earnings per share. The company’s revenue for the quarter was up 18.5% compared to the same quarter last year. As a group, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.58 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the transaction, the chief operating officer now directly owns 635,363 shares in the company, valued at $40,129,527.08. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 26,007 shares of company stock valued at $1,642,990 in the last 90 days. 12.70% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.